PHENOTYPIC IMPACT OF ETV4 OVEREXPRESSION IN PROSTATE CARCINOGENESIS

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-12-14

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer

  2012influential reference
• Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

  2012cited by this paper
• ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

  2012cited by this paper
• Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition

  2012influential reference
• Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.

  2012cited by this paper
• FTH1 binds to Daxx and inhibits Daxx-mediated cell apoptosis

  2011cited by this paper
• H ferritin gene silencing in a human metastatic melanoma cell line: a proteomic analysis.

  2011cited by this paper
• Genomic and biochemical insights into the specificity of ETS transcription factors.

  2011cited by this paper
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

  2011cited by this paper
• Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells

  2011cited by this paper
• Oncogenic activation of ERG: A predominant mechanism in prostate cancer

  2011cited by this paper
• PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma

  2011cited by this paper
• Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer

  2011cited by this paper
• The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.

  2011cited by this paper
• PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

  2011cited by this paper
• Relative 8q gain predicts disease‐specific survival irrespective of the TMPRSS2‐ERG fusion status in diagnostic biopsies of prostate cancer

  2011cited by this paper
• NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications

  2011cited by this paper
• The significance of strong histone deacetylase 1 expression in the progression of prostate cancer

  2011cited by this paper
• YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion

  2011cited by this paper
• PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53–MDM2 loop

  2010cited by this paper
• The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma

  2010cited by this paper
• Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

  2010cited by this paper
• Molecular genetics of prostate cancer: new prospects for old challenges.

  2010cited by this paper
• How accurate are cancer cell lines?

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010influential reference
• The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

  2010cited by this paper
• Urine biomarkers in prostate cancer

  2010cited by this paper
• The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells.

  2010influential reference
• ETS Transcription Factor Expression and Conversion During Prostate and Breast Cancer Progression

  2010cited by this paper
• Testing mutual exclusivity of ETS rearranged prostate cancer

  2010cited by this paper
• American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010

  2010cited by this paper
• Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

  2010cited by this paper
• Cellular Stress Responses: Cell Survival and Cell Death

  2010cited by this paper
• Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo

  2010cited by this paper
• Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer

  2009cited by this paper
• Epigenetic mechanisms in the biology of prostate cancer.

  2009cited by this paper
• N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

  2009cited by this paper
• ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

  2009cited by this paper
• ETS gene fusions in prostate cancer

  2009cited by this paper
• Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cited by this paper
• Atypical small acinar proliferation in the prostate: clinical significance in 2006.

  2009cited by this paper
• World Cancer Report 2008

  2009cited by this paper
• Clinicopathologic Significance of KIAA1199 Overexpression in Human Gastric Cancer

  2009cited by this paper
• Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

  2009cited by this paper
• Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer

  2009cited by this paper
• TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

  2009cited by this paper
• Inflammatory Atrophy of the Prostate

  2009cited by this paper
• The cancer genome

  2009cited by this paper
• High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancer

  2009cited by this paper
• Diagnostic Uncertainty Expressed in Prostate Needle Biopsies

  2009cited by this paper
• Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.

  2008cited by this paper
• The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

  2008cited by this paper
• Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.

  2008cited by this paper
• Black men are dying from prostate cancer.

  2008cited by this paper
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

  2008cited by this paper
• Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications

  2008cited by this paper
• Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

  2008cited by this paper
• The discovery and application of gene fusions in prostate cancer

  2008cited by this paper
• The array CGH and its clinical applications.

  2008cited by this paper
• Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

  2008cited by this paper
• Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

  2008cited by this paper
• Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

  2008cited by this paper
• Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

  2008cited by this paper
• E1AF promotes mithramycin A-induced Huh-7 cell apoptosis depending on its DNA-binding domain.

  2008cited by this paper
• Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

  2008cited by this paper
• The role of testosterone in the pathogenesis of prostate cancer

  2008cited by this paper
• Androgen receptor and invasion in prostate cancer.

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy.

  2008cited by this paper
• DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.

  2008cited by this paper
• A causal role for ERG in neoplastic transformation of prostate epithelium

  2008cited by this paper
• Role of the TMPRSS2-ERG gene fusion in prostate cancer.

  2008influential reference
• Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer

  2008cited by this paper
• Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.

  2008cited by this paper
• Pathology of benign prostatic hyperplasia

  2008cited by this paper
• Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

  2008cited by this paper
• Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription

  2008cited by this paper
• Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

  2008cited by this paper
• TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

  2008cited by this paper
• Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

  2008cited by this paper
• Concepts of epigenetics in prostate cancer development

  2008cited by this paper
• Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

  2008cited by this paper
• A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

  2008cited by this paper
• Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

  2008cited by this paper
• TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

  2008cited by this paper
• Complex patterns of ETS gene alteration arise during cancer development in the human prostate

  2008cited by this paper
• A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

  2008cited by this paper
• Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.

  2007cited by this paper
• Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.

  2007cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper
• Association of RNASEL Variants with Prostate Cancer Risk in Hispanic Caucasians and African Americans

  2007cited by this paper
• The mammalian epigenome.

  2007cited by this paper
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

  2007cited by this paper
• Inflammation and chronic prostatic diseases: evidence for a link?

  2007cited by this paper
• Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family.

  2007influential reference

• No citing papers are available for this paper.